Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 19, 2026.

Applications of decellularized extracellular matrix in bone and cartilage tissue engineering

Yu Seon Kim, Marjan Majid, Anthony J. Melchiorri and 1 more

Bioengineering & Translational Medicine · 2018 · Review · CC BY

doi:10.1002/btm2.10110

Abstract

Regenerative therapies for bone and cartilage injuries are currently unable to replicate the complex microenvironment of native tissue. There are many tissue engineering approaches attempting to address this issue through the use of synthetic materials. Although synthetic materials can be modified to simulate the mechanical and biochemical properties of the cell microenvironment, they do not mimic in full the multitude of interactions that take place within tissue. Decellularized extracellular matrix (dECM) has been established as a biomaterial that preserves a tissue's native environment, promotes cell proliferation, and provides cues for cell differentiation. The potential of dECM as a therapeutic agent is rising, but there are many limitations of dECM restricting its use. This review discusses the recent progress in the utilization of bone and cartilage dECM through applications as scaffolds, particles, and supplementary factors in bone and cartilage tissue engineering.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.

INTRODUCTION

Regenerative medicine offers the ability to repair injuries that the body fails to heal. Although there are many synthetically designed materials to support tissue regeneration, these materials fall short of fully replicating a tissue's microenvironment.1 Looking to the function of this microenvironment for inspiration has provided insight into how materials used in tissue regeneration can be improved. One potential therapeutic material is the native extracellular matrix (ECM), which is the noncellular component of tissue that provides the structural support and biochemical cues for determining a cell's fate.2 ECM is a natural material that encompasses both the cell microenvironment and biochemical factors for living cells.3, 4 Each tissue type has a specialized ECM structure and composition that modulates cell responses and benefits the survival of cells within that tissue.2 ECM is composed of two major components, collagen and proteoglycans, which are secreted by cells and assembled in a manner specific to individual tissue types. It contains a reservoir of growth factors and cytokines; these send signals that regulate cell proliferation and migration as well as modulate differentiation and phenotypic expression of the cell. Due to its inherent compositional similarity and modulatory abilities of supporting tissue growth and differentiation, the use of tissue‐specific ECM for tissue regeneration has gained popularity, including in the areas of bone and cartilage engineering.

Bone ECM consists of an organic and inorganic phase. The organic phase, mostly type I collagen, provides the tissue with flexibility, while the inorganic phase, mainly consisting of calcium phosphate, specifically hydroxyapatite (HA),5 is the source of bone strength.6 In addition, there are four cell types in bone tissue that contribute to osteogenesis: (a) undifferentiated osteoprogenitor cells, (b) matrix‐depositing osteoblasts, (c) mature osteocytes that no longer deposit matrix, and (d) osteoclasts that resorb bone tissue. In natural maintenance of the tissue as well as in response to injury, these cell types work in conjunction to homeostatically build up and breakdown the matrix.7 Bone tissue is one of the few tissues that can heal itself with little to no formation of scar tissue. However, there is a critical size limit of 2.5 cm for most bone,8 above which regeneration will not occur. In these cases, it is necessary to induce and support osteogenesis to heal the defect.

Cartilage ECM is primarily a collagenous network,3 with varying compositions and types of collagen depending on the cartilage type. Hyaline cartilage is mainly type II collagen, while fibrous cartilage is a mixture of both type I and II collagens.9, 10 Another major component of these networks is proteoglycans. Proteoglycans consist of multiple chains of glycosaminoglycans (GAGs) branching off from a core protein. Aggrecan is the most abundant proteoglycan present in cartilage, of which chondroitin sulfate and keratan sulfate are the main GAG components. Aggrecan is highly anionic at physiological pH and attracts water molecules, which gives cartilage its elastic and swelling properties, allowing it to have high shock absorbance under compressive load.3, 11 Different cartilage types have varying collagen/GAG compositions, giving each type distinct mechanical properties. For instance, knee meniscus, a type of fibrocartilage, is predominantly composed of type I collagen, but it has lower GAG content compared to hyaline cartilages such as articular cartilage. This results in meniscus having a higher tensile modulus and lower compressive modulus compared to articular cartilage.12 Cartilage ECM is maintained solely by chondrocytes, which comprise only 1‐5% of total cartilage volume.13 This low cell density contributes to cartilage tissue having low regeneration capabilities, which is also compounded by the avascular nature of the tissue. In cases when healing does occur, it often yields the formation of fibrous cartilage, which leads to stiffer tissue at the injury site and long‐term performance issues.3, 11 To improve function, regenerative therapies promote the formation of native articular/hyaline cartilage rather than fibrous cartilage.

To process ECM for use in regenerative therapy, the excised tissue must first undergo decellularization. Decellularization refers to the process of treating a tissue with any combination of physical stress and chemical/enzymatic agents to remove cellular components, leaving behind only the noncellular ECM that can be used for therapeutic applications. The specific method of decellularization used depends on the tissue type; for instance, while cartilage tissue is able to undergo a relatively harsh treatment, lung tissue requires a more sensitive decellularization method to preserve its tissue composition.14 The resulting decellularized extracellular matrix (dECM) can then be processed further for different tissue engineering applications. These applications are summarized in Table 1. The main benefit of dECM is that it retains components of the natural cell environment2; with proper decellularization, the complex biomolecular and physical cues in the ECM are preserved and can support cell growth and viability. Unlike in transplanted tissue, dECM has a lower risk for immune response because almost all the cellular DNA is removed.15 However, the decellularization process does present challenges, the foremost of which is maximizing the removal of cellular material while limiting damage to the ECM.15

Although synthetic materials have their benefits, such as tunability of physicochemical properties, they are unable to fully replicate the native microenvironment and structure of the tissue, even with modifications or the addition of bioactive factors.1 Thus, incorporating dECM presents a promising method for creating an environment that better mimics that of native tissue and suits repair of the injury site.

GENERAL METHODS OF DECELLULARIZATION

To retain as much of the tissue's bioactivity as possible while maximizing the removal of nuclear material, the decellularization process must minimize the loss of native ECM components. Implantation of decellularized tissue that has had its nucleic materials incompletely removed or degraded could result in host foreign body reaction, which leads to the formation of fibrous capsule surrounding the implant site.16, 17 This eventually can result in improper tissue remodeling and therefore limit the regenerative potential of the decellularized tissue.18 Preserving the ECM ultrastructure is also important in applications where dECM is not further processed but used as a scaffold by itself. Specific decellularization procedures vary according to the tissue type and can involve a combination of (a) physical, (b) enzymatic, and (c) chemical processes. The most frequently used techniques are discussed below.

2.1. Physical decellularization

Introducing physical stresses such as freeze–thaw and osmotic pressure can result in cell lysis without significantly disrupting the ultrastructure of the tissue. Freeze‐thawing is one of the most widely used physical decellularization methods, during which the formation of ice crystals puncture cell membranes. The cycle is repeated multiple times before the tissue sample can be processed further. Another option is osmotic lysis, during which tissues are placed in either a hypertonic19 or hypotonic solution such as deionized water20 that ruptures the plasma membrane via osmotic shock. Other common physical decellularization methods include hydrostatic pressure,21 sonication,22 and electroporation.23

Tissues that undergo only physical decellularization, specifically freeze‐thawing, are considered to be devitalized but not decellularized, as the cells have been lysed, but the cell debris and genetic material still remain within the processed tissue. These samples are most often processed into particles, during which the tissues go through a combination of freeze‐thawing and lyophilization, and are then ground into powder using a freezer/mill.19, 24, 25, 26, 27 Devitalized tissue particles have been shown to have higher quantities of ECM components, such as GAGs, than those that have been additionally treated with chemical/enzymatic decellularization methods.19, 25 However, there are safety concerns of possible immune responses that could result from residual cellular material. There have also been conflicting reports on whether the increase in ECM components leads to a better cellular response.19 For instance, rat bone marrow‐derived mesenchymal stem cells (MSCs) cultured with devitalized cartilage (DVC) particles had lower cell viability and chondrogenic gene expression levels than MSCs cultured with decellularized cartilage (DCC) particles.19 This difference may be due to the increased quantity of GAGs in devitalized tissue causing the particles to be too dense for adequate cell infiltration.19

Physical decellularization is the least disruptive decellularization method, with most of the ECM components and structure left intact after treatment.28 However, physical decellularization alone cannot completely remove cellular debris from the tissue. Often it is used in conjunction with additional chemical or enzymatic methods.29 Similarly, incubating a tissue sample in chemical or enzymatic agents without physical agitation does not result in an acceptable degree of decellularization due to limited diffusion into the tissue. Therefore, a combination of all three methods has a synergistic effect where physical agitation enhances the tissue penetration depth of chemical and enzymatic agents, thereby facilitating the removal of lysed cell material.30, 31

2.2 Chemical decellularization

Chemical methods of decellularization can largely be divided into two subcategories where tissue samples can be treated with either (a) acidic or basic conditions or (b) detergents. Treating tissues with acids or bases results in cell degradation and the removal of cellular components such as nucleic acids. The degree of successful decellularization will vary according to the type and concentration of the acid/base being used, processing time, and the type of tissue being treated. Bases are considered the harsher option of the two and can result in significant loss of GAGs.32, 33 Preservation of GAGs during decellularization is important to maintain tissue mechanical properties (e.g.,tensile, viscoelastic properties)33, 34 and to retain growth factors in the tissue,35, 36 the latter of which have been linked with enhanced biocompatibility in vitro.37 Except for cases where reduction of GAGs is a desired outcome,20 alkaline treatment is rarely used as an option for decellularization of bone and cartilage tissue. Peracetic acid is frequently used to decellularize thin tissues such as small intestine submucosa (SIS). For more dense tissues such as menisci, formic acid is considered the best choice for removing both collagen and GAGs.38

Chemical decellularization can also be performed through the use of detergents. Three main types of detergents are used: nonionic, ionic, and zwitterionic. Nonionic detergents such as Triton X‐100 lyse cells through insertion into the lipid bilayer, disrupting the cellular membrane. While disrupting lipid interactions, these largely preserve protein–protein interactions.39 Proteins are solubilized, but their native structure mostly remains intact.18 Ionic detergents such as sodium dodecyl sulfate (SDS) are known as denaturing detergents; they disrupt cell membranes and also completely denature proteins. Generally, ionic detergents are considered harsher than nonionic detergents, and they are more detrimental to the ECM structure. For instance, MSCs seeded on tendons treated with SDS had a lower viability and distribution throughout the tissue than cells seeded on tissues treated with Triton X‐100.40 Zwitterionic detergents such as 3‐([3‐cholamidopropyl] dimethylammonio)‐1‐propanesulfonate (CHAPS) have a net zero charge and show characteristics of both ionic and nonionic detergents.15 Although zwitterionic detergents result in less denaturing of proteins compared to ionic detergents, they also tend to remove less cellular material than ionic detergents.41, 42

2.3 Enzymatic decellularization

Enzymatic decellularization is most often used directly after chemical decellularization to further facilitate the cell degradation and the removal of residual nuclear material from the tissue. Nucleases and proteases are the most widely used enzymes for enzymatic decellularization. Nucleases, such as deoxyribonuclease and ribonuclease, act directly on DNA and RNA chains, respectively, to hydrolyze phosphodiester bonds. Proteases, such as trypsin, act on proteins by hydrolyzing peptide bonds. Trypsin is a serine protease that cleaves the carbonyl side of lysine or arginine residues. Because of its specific activity on peptides, trypsin treatment can severely disrupt ECM proteins such as elastin and collagen.15 Enzymatic methods are frequently used in conjunction with chelating agents such as ethylenediaminetetraacetic acid (EDTA), which disrupt cell adhesion to ECM proteins by sequestering metallic ions such as calcium.15

2.4 Evaluation of the degree of decellularization

Measuring the amount of double‐stranded DNA (dsDNA) in dECM is the current gold standard for evaluating the degree of successful decellularization. By comparing the amount of DNA in tissue samples before and after decellularization using quantitative assays such as PicoGreen,43 it is possible to make general conclusions on whether the sample has been sufficiently decellularized. Crapo et al. have suggested three minimum criteria that tissues should satisfy to be considered successfully decellularized: (a) tissue samples should contain < 50 ng of dsDNA per mg of dry ECM, (b) any remaining DNA fragments should be smaller than 200 base pairs, and (c) the tissue should not have visible nuclear material when stained with DAPI or hematoxylin & eosin.15 In addition to quantifying the remaining cellular material, it is also important to evaluate both the macroscopic change in the ECM structure and the biochemical composition to ensure minimal disruption of the ECM composition. For applications where the whole tissue is decellularized without being further broken down into smaller particles, imaging techniques such as scanning/transmission electron microscopy40, 44 and microcomputed tomography45, 46 can be used to compare the structure of ECM both before and after decellularization. For more quantitative analyses, the amount of sulfated glycosaminoglycans (sGAGs) and collagen can be evaluated using dimethylmethylene blue (DMMB)47 and hydroxyproline assays,48 respectively. These assays are well‐established and can help investigators draw more concrete conclusions about the efficacy of the decellularization protocol used.

Decellularized ECM as a scaffold

One of the simplest methods of using dECM is as a scaffold that maintains its original geometry. The biggest advantage of this method is that, compared to other processing methods that completely pulverize the dECM, using it as an unprocessed scaffold suggests that the tissue retains a large portion of its original ECM architecture. dECM can be prepared from various tissue types to accommodate different compositions, topographies, and mechanical properties.49 However, such benefits can only be obtained if (a) most of the cell debris is removed from the tissue without destruction of essential ECM components such as GAGs and collagen fibers and (b) the dECM can be thoroughly recellularized. As a result, recent literature has focused on the effects of decellularization methods on the composition and ultrastructure of the resulting tissue and the degree of recellularization.

Bone

The development of a decellularized bone scaffold has been motivated by the need to improve the biocompatibility of allograft bone50 and the benefit of preserving the bone's native structure.45, 46 Xu et al. successfully decellularized annulus fibrosus tissue from porcine spine while maintaining its macroscopic structure.45 Different types of decellularization methods showed various effects on the retention of ECM molecules; trypsin treatment resulted in lowest GAG content, followed by SDS and Triton X‐100. All three methods did not result in significant loss of collagen.45 Smith et al. investigated the effect of donor age on the resulting osteogenic capacity of the isolated human bone following decellularization.46 The authors reported that bone from an old donor (≥70 years age) was more porous and less dense than that from a young donor (≤50 years age), but the tissues otherwise had similar composition (e.g.,mineral density, calcium/phosphate ratio). MSCs seeded on decellularized bones from older donors expressed higher levels of osteogenic markers than those seeded on decellularized bones from young donors, which the authors attributed to enhanced porosity. Decellularized bone has also been subjected to further modifications, such as collagen/HA coating.51 When type I collagen solutions were applied to the surface of decellularized porcine cancellous bone, the coating modulated the stiffness of the matrix. Higher collagen concentration led to higher matrix stiffness compared to uncoated matrices, which in turn guided more robust differentiation of seeded MSCs into osteogenic lineages.

Cartilage

Due to its dense ECM, decellularizing cartilage and seeding cells afterward have proven challenging. Multiple methods have thus been developed to improve the aforementioned processes, albeit with limited success. Luo et al. introduced channels into full‐thickness porcine cartilage discs, which acted as conduits for fluids and cells to penetrate into the tissue.52, 53 These channels supported cell viability and attachment while also allowing the cells to align with the native collagen architecture. However, the degree of recellularization throughout the cartilage tissue was still limited compared to native tissue, indicating that the formation of physical channels was not enough to allow sufficient recellularization. After reports claiming that proteoglycans in cartilage inhibited cell adhesion,54, 55 there have also been attempts to enhance cell adhesion following decellularization by removing GAGs from cartilage tissue.56, 57, 58, 59 Bautista et al. added chondroitinase ABC during decellularization to aid the removal of GAGs from porcine articular cartilage.60 The authors also created channels through the tissue, which was then overlaid with cell suspension and centrifuged (to pull the cells deeper into the tissue). These treatments, although successful in enhancing decellularization, did not improve recellularization rates. Tyler et al. conducted an in vivo study using the ovine osteochondral defect model, during which a decellularized osteochondral allograft was implanted and studied after 12 weeks.61 The constructs were remodeled by infiltrating cells, but the cell density was still lower than that of healthy cartilage, resulting in a low GAG concentration within the decellularized implant.

Although maintaining the native architecture during decellularization has its benefits, dECM scaffolds are limited to certain geometries and cannot easily be scaled. To circumvent this, decellularized tissue can be pulverized and freeze‐dried into particles that are packed into molds, making it possible to fabricate highly porous dECM scaffolds of varying geometry.59, 62, 63, 64, 65 Architectural attributes like the size of pores within these scaffolds can impact the behavior of seeded cells. Almeida et al. prepared coarse and fine dECM particles by processing porcine cartilage using two different methods (homogenizer and cryomill, respectively).59 By changing the concentration of dECM particle slurry, the authors were able to prepare scaffolds with pore sizes ranging from 32 ±12 to 65 ±20 μm. Scaffolds with larger pore sizes resulted in better cell infiltration, proliferation and higher chondrogenic activity in vitro. To maintain structural fidelity and resolution of architectural features, these scaffolds usually undergo physical crosslinking such as UV irradiation or dehydrothermal treatment (DHT).36, 66 Gawlitta et al. prepared porous scaffolds from decellularized equine cartilage and crosslinked them via UV irradiation.63 The scaffolds were seeded with MSCs and were subcutaneously implanted in immunocompromised rats to measure osteoinductive capacity. MSCs within the dECM‐based porous scaffolds experienced chondrogenic differentiation which allowed for enhanced endochondral bone formation.63

The behavior of cells and physical properties of the scaffolds can be affected by different crosslinking schemes.62, 67 Rowland et al. reported that physical crosslinking, specifically DHT crosslinking, resulted in better chondrogenic response from encapsulated MSCs than did chemical crosslinking.62 However, a study conducted by Almeida et al. showed chemical crosslinking did not limit the chondroinductive capacity when compared to a scaffold crosslinked via DHT.59 These contradictory results indicate that further studies must be conducted to fully understand the impact of either physical or chemical crosslinking on dECM‐based porous scaffolds and their ability to induce differentiation in stem cells.

Solubilized dECM as a hydrogel

Solubilized dECM is created when dECM is further digested using pepsin, creating a homogeneous solution that can undergo thermal gelation at physiological temperature and pH. As the tissue is homogenized, solubilized dECM does not preserve either the architecture or topology of the natural ECM. One of the earliest attempts to create such tissue‐derived hydrogels was made with decellularized SIS.68 The tissue, following decellularization, was pulverized in liquid nitrogen, and the resulting powder was digested in an acidic buffer containing pepsin. Digested SIS demonstrated thermally responsive gelation by maintaining the pH and ionic strength of the solution at a physiologically relevant level and placing the solution in a mold at 37 °C for 30 min to an hour.

The method of fabricating a hydrogel using solubilized dECM has remained similar over the course of its use and is as follows: (a) tissue decellularization, (b) digestion with pepsin in acidic buffer, (c) neutralization of the buffer to physiological pH/salt concentration using 10 × phosphate buffered saline (PBS) and NaOH, and (d) formation of the hydrogel by bringing the temperature to 37 °C. Although pepsin digestion is the most widely used method for solubilizing dECM, the bioactivity of pepsin‐digested dECM remains controversial.69, 70 To this end, several studies have explored the possibility of using urea to extract soluble components of dECM.71, 72 Urea is a chaotropic agent that disrupts hydrogen bonding, resulting in the denaturation of proteins and the disruption of interactions between lipids and proteins. Urea‐extracted dECM had higher concentrations of small and moderate MW proteins compared to pepsin‐digested dECM, which consisted primarily of collagen chains.71 When used as a supplement in two‐dimensional/three‐dimensional (3D) cell culture, urea‐extracted dECM also promoted tissue‐specific differentiation of MSCs.72 Chondrogenic activity was upregulated when the urea‐extracted dECM was mixed with gelatin methacrylate (GelMA) hydrogels, although the effect was short term.72

Bone

The motivation for developing solubilized bone dECM comes from the inconsistent results obtained with delivering demineralized bone particles into bone defect sites using carriers such as sodium hyaluronate or gelatin.73, 74, 75 Sawkins et al. have demonstrated that both demineralized and decellularized bovine bone ECM, after undergoing pepsin digestion, could form a thermally responsive hydrogel.76 Both demineralized and decellularized bone ECM consisted primarily of randomly oriented type I collagen fibers and could support the growth of mouse primary calvarial cells. Cells encapsulated in dECM hydrogels showed a higher proliferation rate than those in demineralized bone or collagen type I hydrogels. Paduano et al. demonstrated that dental pulp stem cells (DPSCs), when seeded on dECM derived from bovine tibia, underwent odontogenic differentiation in vitro.77 Adding exogenous growth factors such as basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) to dECM hydrogels had a synergistic effect on the degree of differentiation.77 In a series of studies published in 2014, Smith et al. used solubilized bovine bone dECM mixed with alginate as a carrier hydrogel to deliver cells and growth factor‐releasing microparticles to support the regeneration of skeletal tissue.78, 79 Solubilized dECM was injected between the segmental defect of embryonic Day 11 chick femur and cultured ex vivo for 10 days after which the degree of bone tissue formation was evaluated. Alginate/solubilized dECM hydrogels incorporating human bone marrow stem cells (BMSCs) and osteogenic growth factor‐loaded poly(lactic‐co‐glycolic acid) (PLGA) microparticles induced higher collagen deposition, indicating osteoid matrix deposition (Figure 1).78 With its inherent ability to undergo thermogelation, solubilized dECM is a versatile platform that can be combined with other materials to form a potent and tunable hydrogel capable of inducing bone regeneration through effective cell growth and differentiation.

Cartilage

Wu et al. were able to fabricate a thermoresponsive hydrogel from porcine menisci dECM, which could support the growth of both seeded and encapsulated chondrocytes in vitro.80 Digested dECM solutions were subcutaneously injected into mice and gelled within 30 minutes. The resulting hydrogel showed good cytocompatibility without causing an inflammatory reaction in vivo. Kwon et al. have also shown that it is possible to use articular cartilage‐derived dECM as an injectable drug delivery vehicle.81 In this study, the hydrogel was injected subcutaneously into rats and showed sustained release of bovine serum albumin over 10 days in vivo. Like solubilized bone dECM, cartilage solubilized dECM can be used to deliver cells, drugs, and other bioactive molecules for cartilage regeneration.

The most common limitation of hydrogels formed from solubilized dECM is poor mechanical properties. For this reason, different approaches to enhance the mechanical properties of solubilized dECM have been implemented, including mixing with biological polymers, such as alginate,78, 79 and crosslinking using physical, UV photochemical,26, 62, 82 or chemical83, 84 methods. Although such treatments create hydrogels that are physically stable, they can also limit the chondrogenic capacity of the hydrogel. For instance, Cheng et al. showed that although crosslinking the hydrogel using genipin prevented cell‐mediated contraction, increasing the crosslinking density reduced cell infiltration and chondrogenic activity, possibly due to a decrease in pore size and a reduction in adhesion sites.83 This can be overcome through combinatorial material techniques, including the addition of nonsolubilized dECM particles to a hydrogel. For example, Beck et al. showed that adding nonsolubilized dECM particles to a solubilized DVC hydrogel demonstrated enhancement of both the mechanical properties of a solubilized DVC hydrogel paste and chondrogenic gene expression from rat MSCs within the hydrogel both in vivo and in vitro.26

Cell‐laid matrix

ECM ornamentation or decoration is the process of coating a scaffold (often one derived from synthetic materials) with a layer of cell‐secreted ECM and is generally carried out in three steps: (a) cells are seeded onto a prefabricated synthetic or biological scaffold and cultured to promote ECM deposition, (b) the scaffold is decellularized, leaving behind the ECM‐ornamented scaffold, and (c) the ECM‐ornamented scaffold is recellularized for use as a regenerative therapy.85 The layer of dECM provides cell adhesion sites and biochemical cues that improve cell–material interactions compared to cell adhesion onto a bare scaffold. ECM ornamentation thus primes the scaffold for better cell attachment and more robust cell growth/proliferation.85 This process has been demonstrated on multiple types of scaffolds, such as 3D‐printed scaffolds,4, 85, 86 electrospun scaffolds,87, 88, 89, 90 and decellularized tissue.91, 92, 93

Bone

Pati et al. performed an in vitro study where they 3D‐printed a scaffold of combined polycaprolactone (PCL), PLGA, and β‐tricalcium phosphate (TCP).4 The scaffold was seeded with human inferior turbinate tissue‐derived mesenchymal stromal cells (hTMSCs) to ornament it with cell‐laid bone ECM then decellularized to leave behind the ECM‐ornamented scaffold. After seeding with new hTMSCs, they showed that the presence of bone ECM significantly improved further deposition of mineralized matrix and enhanced osteogenic differentiation of the hTMSCs. They also performed an in vivo ectopic rat study with ECM‐ornamented scaffolds recellularized with human BMSCs. The ECM‐ornamented scaffold showed increased bone formation compared to the same scaffold with no ECM (Figure 2a).4 Kumar et al. 3D printed a PCL‐HA scaffold on which they seeded osteoblasts to deposit mineralized ECM.85 The scaffold was decellularized, leaving only the mineralized ECM, then reseeded with osteoblasts. The authors observed enhanced expression of the skeletal protein actin and the adhesion protein vinculin compared to undecorated scaffolds (Figure 2b). They also found improved cell–scaffold and cell–cell interactions, which correlate to increased cell adhesion, growth, and motility compared to bare PCL‐HA scaffolds.85 Electrospun scaffolds have also been used as templates for cell‐laid ECM.87, 88, 90 Thibault et al. seeded rat MSCs on electrospun PCL scaffolds and cultured them in well plates with osteogenic media for 12 days.87 The resulting ECM‐ornamented scaffolds triggered higher amount of calcium deposition from seeded MSCs when compared to bare PCL scaffolds, indicating that the presence of ECM coating enhanced the degree of osteogenic differentiation. To improve the distribution of ECM proteins throughout the thickness of electrospun PCL scaffolds, Liao et al. cultured MSC‐seeded scaffolds in flow perfusion bioreactors for up to 16 days.90 Longer duration of the culture resulted in better distribution and increased amount of ECM proteins and calcium, resulting in increased alkaline phosphatase activity and calcium deposition by seeded MSCs.

Aside from synthetic polymers, using decellularized SIS for ECM ornamentation has also been investigated.93, 94 Zhang et al. fabricated SIS ornamented with osteoblast‐secreted ECM that promoted both adhesion and proliferation of seeded adipose‐derived stem cells (ADSCs). Once implanted, the construct enhanced bone regeneration in vivo compared to non ECM‐ornamented or non ADSC‐seeded SIS.94

Cartilage

For cartilage regeneration, the same coating techniques can be applied. However, there has also been substantial work in applying these techniques in tissue culture flasks to promote ECM deposition and study its effects in cell culture.95, 96, 97, 98 Hoshiba et al. cultured chondrocytes at different passages (0, 2, and 6) on tissue culture flasks for 10 days before decellularizing and collecting the ECM.95 ECM secreted by chondrocytes at different passages had different compositions, which impacted the behavior of chondrocytes that were seeded on dECM: cells seeded on P0 chondrocyte‐secreted ECM expressed higher levels of ACAN and COL2A1 (markers for aggrecan and type II collagen, respectively) than both uncoated and P2 and P6 chondrocyte‐secreted ECM groups, indicating that dECM limited the dedifferentiation of seeded chondrocytes.

ECM derived from these cell cultures can be used in translatable scaffolding strategies. Tang et al. cultured autologous bone marrow‐derived MSCs on tissue culture flasks, collected the cell‐deposited ECM, and freeze‐dried it to fabricate a porous cell‐derived scaffold.97, 98 Chondrocytes seeded on the dECM scaffold synthesized more GAGs and type II collagen than those seeded on atelocollagen (scaffold derived from bovine Achilles tendon fibers). A similar trend was observed in vivo, where dECM scaffold groups not only contained more GAGs, but also had a higher compressive modulus than the control group.97 The scaffold was also used with bone marrow stimulation (BMS) technique in a rabbit model, which further enhanced the degree of tissue regeneration compared to BMS only treatment.98

ECM ornamentation directly addresses many of the limitations of other tissue‐engineered dECM applications. As cells are seeded onto prefabricated scaffolds, complex geometries and tunable mechanical, physical, and biological properties can still be achieved through processes such as 3D printing of a synthetic scaffold while still utilizing the biological cues of natural ECM.85 It can limit or prevent the disadvantages of other techniques, such as the effect of high pressure extrusion on cells during 3D printing, the dimensional mismatch between defect site and fabricated scaffold in implantable hydrogels, and the lack of structural support in dECM alone.4 In addition, cell‐directed ECM‐ornamenting offers a more physiologically relevant microenvironment formation than a simple, manual coating with dECM, as coating can yield fragmented ECM components that do not accurately represent native ECM.4 Thus, by employing ECM ornamentation, scaffolds can be fabricated from tunable synthetic materials in complex geometric and synergistically incorporate natural ECM proteins to better recapitulate the ECM environment.4

Bioink

Another interesting application of dECM is its use as a 3D printable bioink. 3D printing, or additive manufacturing, is the creation of three‐dimensional structures layer‐by‐layer. The most common method of 3D printing bioinks is extrusion printing, during which the material is deposited via a mechanically controlled syringe into a desired geometry.99 This technique is capable of creating complex architectures by depositing multiple materials with high spatial control. These complex geometries can be obtained through the design of a computer model to match a defect site identified via medical imaging modalities such as MRI or CT.99 Bioactive molecules such as growth factors and different cell types can be incorporated into the scaffold to better mimic complex tissue architectures, such as the transition from bone to cartilage in an osteochondral defect.100 Porosity can also be tightly controlled within 3D printed constructs to ensure adequate gas and waste exchange as well as nutrient delivery.100

Cartilage

Pati et al. have demonstrated the fabrication of cell‐seeded bioinks for 3D printing applications.101 Cartilage dECM was recellularized with hTMSCs and printed into a porous PCL framework to generate a cartilage tissue scaffold. The authors created wells by first printing multiple layers of a PCL lattice into which a bioink could be deposited (Figure 3).101 This process was repeated to create a scaffold several millimeters in height. Seeded hTMSCs exhibited chondrogenic differentiation and showed increased cell viability on the dECM printed scaffold compared to PCL alone.

In addition to cartilage, efforts have been made towards creating bioinks for several other tissue types such as cardiac muscle, skeletal muscle, and liver tissues. Skardal et al. have developed a PEG‐crosslinked, hyaluronic acid/gelatin‐based modular hydrogel system which allows for enhanced control of the biochemical and mechanical properties of the material.102 By utilizing two crosslinkers and two separate polymerization steps, the authors were able to fabricate a bioink that has a low enough viscosity to be printed and, following printing, increase the elastic modulus of the scaffold through a secondary polymerization step. dECM from different tissues (e.g.,liver, cardiac, skeletal) have been used with this tunable hydrogel system to formulate bioinks that replicate not only the physical but also the biological properties of the representative tissue.102

Utilizing dECM on its own as a bioink for 3D printing is challenging due to its low viscosity and mechanical instability.101, 103 Bulk hydrogels formed using solubilized dECM only reach stiffnesses similar to or slightly better than that of pure collagen gels71 and have very slow gelation times, ranging from 30 minutes to an hour.104, 105 Although increasing the weight percent of a dECM hydrogel can improve its stiffness,106 using such methods for 3D printing is limited as the stiffness of the dECM bioink must be low enough to achieve a viscosity that enables dECM to be extruded through the needle. As such, multiple efforts have been devoted to enhancing the printability of dECM bioinks and the mechanical stability of printed scaffolds by combining them with secondary polymer frameworks,101 mixing them with synthetic polymers,102 and using crosslinkers.103 For instance, adding 0.02% vitamin B2 to a 2% heart dECM bioink and UV‐crosslinking the construct after each layer allowed the final construct to reach a compressive modulus of 15.74 kPa, compared to that of a non UV‐crosslinked construct at 0.18 kPa.103 For applications such as bone tissue where much higher moduli are required, dECM bioinks can be combined with 3D printed porous PCL scaffolds, which can reach compressive moduli in the MPa range.107 In addition, there have also been efforts to develop shear‐thinning hydrogels that can flow through the needle and retain their shape after they have been printed.108, 109, 110 Such approaches may be translated into the printing of dECM to improve its printability.

Decellularized ECM particles

Rather than being used as a standalone scaffold, dECM can be milled into particles that contain ECM components inherent to the tissue type and can provide binding sites for cells. These particles can then be combined with nonbioactive synthetic or biological scaffolds to form a composite scaffold that have tissue‐specific bioactivity. This flexibility allows dECM particles to be incorporated into various types of scaffolds, such as (a) hydrogels, (b) electrospun scaffolds, and (c) 3D‐printed scaffolds.

Hydrogels

Townsend et al. combined HA, hyaluronic acid, and DCC dECM particles in PBS to fabricate a colloidal suspension with a paste‐like consistency that was shown to enhance bone regeneration in vivo.111 Cartilage dECM particles have also been incorporated in type I collagen gels and have shown to enhance chondrogenic gene expression from MSCs encapsulated within the gels. The effect was amplified when the constructs were cultured in chondrogenic media containing transforming growth factor beta‐3 (TGF‐β3).112 To enhance the retention of dECM particles inside a hydrogel, Beachley et al. chemically crosslinked dECM particles with modified GAGs (chondroitin sulfate, hyaluronic acid) via carbodiimide chemistry.113 Constructs containing bone dECM particles enhanced in vivo bone formation when compared to hydrogels that did not contain dECM particles.

Electrospun scaffolds

dECM particles can be incorporated into electrospun scaffolds either during27 or after electrospinning.114 Garrigues et al. dissolved dECM particles in isopropanol and added PCL to increase the solution's viscosity for electrospinning.27 The resulting dECM‐containing electrospun scaffolds showed higher sGAG content and increased collagen synthesis activity from seeded ADSCs compared to PCL scaffolds. Masaeli et al. captured dECM particles on the surface of electrospun polyhydroxyalkanoate via carbodiimide chemistry (Figure 4a).114 Human chondrocytes and ADSCs seeded on dECM‐modified scaffolds expressed higher levels of chondrogenic genes compared to cells seeded on unmodified scaffolds, indicating that the addition of dECM particles could prevent dedifferentiation of chondrocytes and guide the chondrogenic differentiation of ADSCs. Such treatments improved chondrogenic activity from seeded chondrocytes and MSCs without impacting the scaffold's mechanical properties.

3D‐printed scaffolds

3D printing of PCL fibers is a relatively well‐characterized method used to create porous scaffolds for tissue engineering applications with specific focus on bone tissue regeneration.107, 115, 116, 117 To enhance tissue growth, PCL has been combined with bioactive components or minerals such as HA for printing,118, 119, 120 and recently, there have been efforts to incorporate dECM particles to improve bioactivity of PCL scaffolds.121, 122 Hung et al. have successfully printed porous dECM‐PCL hybrid scaffolds with varying amounts of bone dECM particles and reported that ADSCs better adhered to a printed fiber surface and expressed higher levels of osteogenic gene markers compared to PCL alone (Figure 4b).121 dECM particle‐containing scaffolds also generated greater bone volume in vivo. In a similar study, Nyberg et al. performed an in vitro study to assess the behavior of human ADSCs seeded on 3D‐printed PCL scaffolds incorporating bone dECM particles.122 The authors observed enhanced bone deposition and increased expression of osteogenic genes such as osteonectin compared to PCL scaffolds containing nonbiological components commonly used to promote osteogenesis such as HA or TCP. This change in cellular response was attributed to the presence of collagen, as well as the natural apatite structure in dECM particles.122

Particle aggregates

Cell‐seeded dECM particles can be delivered into the defect site as a particle aggregate.123, 124 Yin et al. generated dECM particles from goat articular cartilage. These dECM particles were then seeded with MSCs and aggregated in a rotary cell culture system.123 Teng et al. cultured cartilage‐like tissue by culturing chondrocyte spheroids in suspension in vitro, which were subsequently decellularized and milled into particles.124 In both cases, dECM particles not only induced chondrogenic behavior from seeded MSCs in vitro, but the MSC/particle aggregate also promoted osteochondral defect repair in vivo.

SUMMARY AND FUTURE PERSPECTIVES

Decellularized ECM is a tissue‐derived biomaterial that can be used as a bioactive component for tissue engineering applications. The versatility of dECM allows it to be processed for various applications, from a whole tissue scaffold to a digested solution that could be used as a bioink for 3D printing. Many dECM studies have shown promising results; the addition of dECM frequently exhibited enhanced regenerative capabilities both in vitro and in vivo and guided the differentiation of seeded stem cells along tissue‐specific lineages even without the addition of exogenous growth factors.

There are, however, limitations to the use of dECM in standard clinical treatments. First, there are significantly different reported methods of dECM tissue processing. With individual studies exploring different combinations of decellularization methods and following flexible guidelines, it is difficult to draw conclusions on which method is best for a specific application. Additional guidelines that not only discuss the removal of nuclear material but also the retention of ECM molecules would contribute greatly to standardized decellularization procedures. Balancing the constraints between removing enough cellular material so as not to elicit an immune response while maintaining ECM composition to preserve bioactivity is a challenge that requires further investigation. Furthermore, tissue sources and storage conditions before being processed for decellularization also influence the quality of dECM, resulting in batch‐to‐batch differences even within the same tissue type. Universally accepted quality control measures for tissue sourcing and storage of dECM would prove beneficial in creating a more reliable and repeatable system.

To summarize, utilization of dECM in tissue engineering applications is still in development and a large portion of the current work still focuses on exploring the effects of different decellularization methods on the biochemical composition of dECM. The results from studies with similar applications are oftentimes contradictory partly because these studies rarely follow the same procedures. In addition, variability in tissue processing—from isolating the tissue to decellularizing—results in low reproducibility. Thus, further studies are necessary if the relationship between the decellularization process and the resulting composition of dECM is to be better understood. General decellularization guidelines that could widely be agreed upon by investigators will pave the way for a more standardized field of tissue decellularization. In addition, the development of methods to enhance the physicochemical properties of dECM while harnessing its native regenerative capacities will be the key to providing viable therapeutic applications for bone and cartilage tissue regeneration.

References 124

  1. 1.

    Jung JP, Bhuiyan DB, Ogle BM. Solid organ fabrication: comparison of decellularization to 3D bioprinting. Biomater Res. 2016;20(1):20–27..

    Not in our library10.1186/s40824-016-0074-2

  2. 2.

    Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 2010;123(24):4195‐4200..

    Not in our library10.1242/jcs.023820

  3. 3.

    Gentili C, Cancedda R. Cartilage and bone extracellular matrix. Curr Pharm Des. 2009;15(12):1334‐1348..

    Not in our library10.2174/138161209787846739

  4. 4.

    Pati F, Song TH, Rijal G, Jang J, Kim SW, Cho DW. Ornamenting 3D printed scaffolds with cell‐laid extracellular matrix for bone tissue regeneration. Biomaterials. 2015;37:230‐241..

    Not in our library10.1016/j.biomaterials.2014.10.012

  5. 5.

    Alford AI, Kozloff KM, Hankenson KD. Extracellular matrix networks in bone remodeling. Int J Biochem Cell Biol. 2015;65:20‐31..

    Not in our library10.1016/j.biocel.2015.05.008

  6. 6.

    Madhurakkat Perikamana SK, Lee J, Lee Y, et al. Materials from mussel‐inspired chemistry for cell and tissue engineering applications. Biomacromolecules. 2015;16(9):2541‐2555..

    Not in our library10.1021/acs.biomac.5b00852

  7. 7.
  8. 8.

    Schemitsch EH. Size matters: defining critical in bone defect size! J Orthop Trauma. 2017;31:S20‐S22..

    Not in our library10.1097/bot.0000000000000978

  9. 9.

    Sophia Fox AJ, Bedi A, Rodeo SA. The basic science of articular cartilage: structure, composition, and function. Sports Health. 2009;1(6):461‐468..

    Not in our library10.1177/1941738109350438

  10. 10.

    Chen J‐L, Duan L, Zhu W, Xiong J, Wang D. Extracellular matrix production in vitro in cartilage tissue engineering. J Transl Med. 2014;12(1):88.

    Not in our library10.1186/1479-5876-12-88

  11. 11.
  12. 12.

    Almarza AJ, Athanasiou KA. Design characteristics for the tissue engineering of cartilaginous tissues. Ann Biomed Eng. 2004;32(1):2‐17..

    Not in our library10.1023/b:abme.0000007786.37957.65

  13. 13.
  14. 14.

    Bruyneel AAN, Carr CA. Ambiguity in the presentation of decellularized tissue composition: the need for standardized approaches. Artif Organs. 2017;41(8):778‐784..

    Not in our library10.1111/aor.12838

  15. 15.

    Crapo PM, Gilbert TW, Badylak SF. An overview of tissue and whole organ decellularization processes. Biomaterials. 2011;32(12):3233‐3243..

    Not in our library10.1016/j.biomaterials.2011.01.057

  16. 16.

    Nagata S, Hanayama R, Kawane K. Autoimmunity and the clearance of dead cells. Cell. 2010;140(5):619‐630..

    Not in our library10.1016/j.cell.2010.02.014

  17. 17.

    Aamodt JM, Grainger DW. Extracellular matrix‐based biomaterial scaffolds and the host response. Biomaterials. 2016;86:68‐82..

    Not in our library10.1016/j.biomaterials.2016.02.003

  18. 18.

    Keane TJ, Swinehart IT, Badylak SF. Methods of tissue decellularization used for preparation of biologic scaffolds and in vivo relevance. Methods. 2015;84:25‐34..

    Not in our library10.1016/j.ymeth.2015.03.005

  19. 19.
  20. 20.

    Schwarz S, Koerber L, Elsaesser AF, et al. Decellularized cartilage matrix as a novel biomatrix for cartilage tissue‐engineering applications. Tissue Eng Part A. 2012;18(21–22):2195‐2209..

    Not in our library10.1089/ten.tea.2011.0705

  21. 21.
  22. 22.

    Oliveira AC, Garzón I, Ionescu AM, et al. Evaluation of small intestine grafts decellularization methods for corneal tissue engineering. PLoS One. 2013;8(6):e66538.

    Not in our library10.1371/journal.pone.0066538

  23. 23.

    Philips M, Maor E, Rubinsky B. Nonthermal irreversible electroporation for tissue decellularization. J Biomech Eng. 2010;132(9):091003.

    Not in our library10.1115/1.4001882

  24. 24.

    Almeida HV, Eswaramoorthy R, Cunniffe GM, Buckley CT, O'Brien FJ, Kelly DJ. Fibrin hydrogels functionalized with cartilage extracellular matrix and incorporating freshly isolated stromal cells as an injectable for cartilage regeneration. Acta Biomater. 2016;36:55‐62..

    Not in our library10.1016/j.actbio.2016.03.008

  25. 25.

    Beck EC, Barragan M, Libeer TB, et al. Chondroinduction from naturally derived cartilage matrix: a comparison between devitalized and decellularized cartilage encapsulated in hydrogel pastes. Tissue Eng Part A. 2016;22(7–8):665‐679..

    Not in our library10.1089/ten.tea.2015.0546

  26. 26.

    Beck EC, Barragan M, Tadros MH, et al. Chondroinductive hydrogel pastes composed of naturally derived devitalized cartilage. Ann Biomed Eng. 2016;44(6):1863‐1880..

    Not in our library10.1007/s10439-015-1547-5

  27. 27.

    Garrigues NW, Little D, Sanchez‐Adams J, Ruch DS, Guilak F. Electrospun cartilage‐derived matrix scaffolds for cartilage tissue engineering. J Biomed Mater Res ‐ Part A. 2014;102(11):3998‐4008..

    Not in our library10.1002/jbm.a.35068

  28. 28.

    Nonaka PN, Campillo N, Uriarte JJ, et al. Effects of freezing/thawing on the mechanical properties of decellularized lungs. J Biomed Mater Res ‐ Part A. 2014;102(2):413‐419..

    Not in our library10.1002/jbm.a.34708

  29. 29.

    Lu H, Hoshiba T, Kawazoe N, Chen G. Comparison of decellularization techniques for preparation of extracellular matrix scaffolds derived from three‐dimensional cell culture. J Biomed Mater Res ‐ Part A. 2012;100 A(9):2507‐2516..

    Not in our library10.1002/jbm.a.34150

  30. 30.

    Hung SH, Su CH, Lee FP, Tseng H. Larynx decellularization: combining freeze‐drying and sonication as an effective method. J Voice. 2013;27(3):289‐294..

    Not in our library10.1016/j.jvoice.2013.01.018

  31. 31.

    Azhim A, Yamagami K, Muramatsu K, Morimoto Y, Tanaka M. The use of sonication treatment to completely decellularize blood arteries: a pilot study. In: Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society, EMBS; IEEE; Boston, MA, 2011, pp.2468–2471. doi:.

    Not in our library10.1109/iembs.2011.6090685

  32. 32.

    Petersen TH, Calle EA, Colehour MB, Niklason LE. Matrix composition and mechanics of decellularized lung scaffolds. Cells Tissues Organs. 2012;195(3):222‐231..

    Not in our library10.1159/000324896

  33. 33.

    Mendoza‐Novelo B, Avila EE, Cauich‐Rodríguez JV, et al. Decellularization of pericardial tissue and its impact on tensile viscoelasticity and glycosaminoglycan content. Acta Biomater. 2011;7(3):1241‐1248..

    Not in our library10.1016/j.actbio.2010.11.017

  34. 34.

    Schmidt MB, Mow VC, Chun LE, Eyre DR. Effects of proteoglycan extraction on the tensile behavior of articular cartilage. J Orthop Res. 1990;8(3):353‐363..

    Not in our library10.1002/jor.1100080307

  35. 35.
  36. 36.

    Yang Z, Shi Y, Wei X, et al. Fabrication and repair of cartilage defects with a novel acellular cartilage matrix scaffold. Tissue Eng Part C Methods. 2010;16(5):865‐876..

    Not in our library10.1089/ten.tec.2009.0444

  37. 37.

    Reing JE, Brown BN, Daly KA, et al. The effects of processing methods upon mechanical and biologic properties of porcine dermal extracellular matrix scaffolds. Biomaterials. 2010;31(33):8626‐8633..

    Not in our library10.1016/j.biomaterials.2010.07.083

  38. 38.

    Chen K, Lin X, Zhang Q, et al. Decellularized periosteum as a potential biologic scaffold for bone tissue engineering. Acta Biomater. 2015;19:46‐55..

    Not in our library10.1016/j.actbio.2015.02.020

  39. 39.

    Gilbert TW, Sellaro TL, Badylak SF. Decellularization of tissues and organs. Biomaterials. 2006;27(19):3675‐3683..

    Not in our library10.1016/j.biomaterials.2006.02.014

  40. 40.

    Burk J, Erbe I, Berner D, et al. Freeze‐thaw cycles enhance decellularization of large tendons. Tissue Eng Part C Methods. 2014;20(4):276‐284..

    Not in our library10.1089/ten.tec.2012.0760

  41. 41.

    White LJ, Taylor AJ, Faulk DM, et al. The impact of detergents on the tissue decellularization process: a ToF‐SIMS study. Acta Biomater. 2017;50:207‐219..

    Not in our library10.1016/j.actbio.2016.12.033

  42. 42.

    Calle EA, Hill RC, Leiby KL, et al. Targeted proteomics effectively quantifies differences between native lung and detergent‐decellularized lung extracellular matrices. Acta Biomater. 2016;46:91‐100..

    Not in our library10.1016/j.actbio.2016.09.043

  43. 43.

    Ahn SJ, Costa J, Emanuel JR. PicoGreen quantitation of DNA: effective evaluation of samples pre‐ or post‐PCR. Nucleic Acids Res. 1996;24(13):2623‐2625..

    Not in our library10.1093/nar/24.13.2623

  44. 44.

    Youngstrom DW, Barrett JG, Jose RR, Kaplan DL. Functional characterization of detergent‐decellularized equine tendon extracellular matrix for tissue engineering applications. PLoS One. 2013;8(5):e64151.

    Not in our library10.1371/journal.pone.0064151

  45. 45.
  46. 46.

    Smith CA, Board TN, Rooney P, Eagle MJ, Richardson SM, Hoyland JA. Correction: human decellularized bone scaffolds from aged donors show improved osteoinductive capacity compared to young donor bone. PLoS One. 2017;12(11):e0177416.

    Not in our library10.1371/journal.pone.0187783

  47. 47.

    Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. BBA ‐ Gen Subj. 1986;883(2):173‐177..

    Not in our library10.1016/0304-4165(86)90306-5

  48. 48.

    Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem. 1996;29(3):225‐229..

    Not in our library10.1016/0009-9120(96)00003-6

  49. 49.

    Yin Z, Chen X, Zhu T, et al. The effect of decellularized matrices on human tendon stem/progenitor cell differentiation and tendon repair. Acta Biomater. 2013;9(12):9317‐9329..

    Not in our library10.1016/j.actbio.2013.07.022

  50. 50.

    Smith CA, Richardson SM, Eagle MJ, Rooney P, Board T, Hoyland JA. The use of a novel bone allograft wash process to generate a biocompatible, mechanically stable and osteoinductive biological scaffold for use in bone tissue engineering. J Tissue Eng Regen Med. 2015;9(5):595‐604..

    Not in our library10.1002/term.1934

  51. 51.

    Chen G, Dong C, Yang L, Lv Y. 3D scaffolds with different stiffness but the same microstructure for bone tissue engineering. ACS Appl Mater Interfaces. 2015;7(29):15790‐15802..

    Not in our library10.1021/acsami.5b02662

  52. 52.

    Luo L, Eswaramoorthy R, Mulhall KJ, Kelly DJ. Decellularization of porcine articular cartilage explants and their subsequent repopulation with human chondroprogenitor cells. J Mech Behav Biomed Mater. 2015;55:21‐31..

    Not in our library10.1016/j.jmbbm.2015.10.002

  53. 53.

    Luo L, Chu JYJ, Eswaramoorthy R, Mulhall KJ, Kelly DJ. Engineering tissues that mimic the zonal nature of articular cartilage using decellularized cartilage explants seeded with adult stem cells. ACS Biomater Sci Eng. 2017;3(9):1933‐1943..

    Not in our library10.1021/acsbiomaterials.6b00020

  54. 54.

    Rich AM, Pearlstein E, Weissmann G, Hoffstein ST. Cartilage proteoglycans inhibit fibronectin‐mediated adhesion. Nature. 1981;293(5829):224‐226..

    Not in our library10.1038/293224a0

  55. 55.

    Yamagata M, Suzuki S, Akiyama SK, Yamada KM, Kimata K. Regulation of cell‐substrate adhesion by proteoglycans immobilized on extracellular substrates. J Biol Chem. 1989;264(14):8012‐8018.

    Not in our library

  56. 56.

    Elsaesser AF, Bermueller C, Schwarz S, Koerber L, Breiter R, Rotter N. In vitro cytotoxicity and in vivo effects of a decellularized xenogeneic collagen scaffold in nasal cartilage repair. Tissue Eng Part A. 2014;20(11–12):1668‐1678..

    Not in our library10.1089/ten.tea.2013.0365

  57. 57.

    Schwarz S, Elsaesser AF, Koerber L, et al. Processed xenogenic cartilage as innovative biomatrix for cartilage tissue engineering: effects on chondrocyte differentiation and function. J Tissue Eng Regen Med. 2015;9(12):E239‐E251..

    Not in our library10.1002/term.1650

  58. 58.

    Obradovic B, Martin I, Padera RF, Treppo S, Freed LE, Vunjak‐Novakovic G. Integration of engineered cartilage. J Orthop Res. 2001;19(6):1089‐1097..

    Not in our library10.1016/s0736-0266(01)00030-4

  59. 59.

    Almeida HV, Cunniffe GM, Vinardell T, Buckley CT, O'Brien FJ, Kelly DJ. Coupling freshly isolated CD44+ infrapatellar fat pad‐derived stromal cells with a TGF‐β3 eluting cartilage ECM‐derived scaffold as a single‐stage strategy for promoting Chondrogenesis. Adv Healthc Mater. 2015;4(7):1043‐1053..

    Not in our library10.1002/adhm.201400687

  60. 60.

    Bautista CA, Park HJ, Mazur CM, Aaron RK, Bilgen B. Effects of chondroitinase ABC‐mediated proteoglycan digestion on decellularization and recellularization of articular cartilage. PLoS One. 2016;11(7):e0158976.

    Not in our library10.1371/journal.pone.0158976

  61. 61.

    Novak T, Seelbinder B, Twitchell CM, Voytik‐Harbin SL, Neu CP. Dissociated and reconstituted cartilage microparticles in densified collagen induce local hMSC differentiation. Adv Funct Mater. 2016;26(30):5427‐5436..

    Not in our library10.1002/adfm.201601877

  62. 62.

    Rowland CR, Lennon DP, Caplan AI, Guilak F. The effects of crosslinking of scaffolds engineered from cartilage ECM on the chondrogenic differentiation of MSCs. Biomaterials. 2013;34(23):5802‐5812..

    Not in our library10.1016/j.biomaterials.2013.04.027

  63. 63.

    Gawlitta D, Benders KEM, Visser J, et al. Decellularized cartilage‐derived matrix as substrate for endochondral bone regeneration. Tissue Eng Part A. 2015;21(3–4):694‐703..

    Not in our library10.1089/ten.tea.2014.0117

  64. 64.

    Kang H, Peng J, Lu S, et al. In vivo cartilage repair using adipose‐derived stem cell‐loaded decellularized cartilage ECM scaffolds. J Tissue Eng Regen Med. 2014;8(6):442‐453..

    Not in our library10.1002/term.1538

  65. 65.

    Chen Y‐C, Chen R‐N, Jhan H‐J, et al. Development and characterization of acellular extracellular matrix scaffolds from porcine menisci for use in cartilage tissue engineering. Tissue Eng Part C Methods. 2015;21(9):971‐986..

    Not in our library10.1089/ten.tec.2015.0036

  66. 66.

    Weadock KS, Miller EJ, Bellincampi LD, Zawadsky JP, Dunn MG. Physical crosslinking of collagen fibers: comparison of ultraviolet irradiation and dehydrothermal treatment. J Biomed Mater Res. 1995;29(11):1373‐1379..

    Not in our library10.1002/jbm.820291108

  67. 67.

    Moradi A, Ataollahi F, Sayar K, et al. Chondrogenic potential of physically treated bovine cartilage matrix derived porous scaffolds on human dermal fibroblast cells. J Biomed Mater Res ‐ Part A. 2016;104(1):245‐256..

    Not in our library10.1002/jbm.a.35561

  68. 68.

    Voytik‐Harbin SL, Brightman AO, Waisner BZ, Robinson JP, Lamar CH. Anonymous. Small intestinal submucosa: a tissue‐derived extracellular matrix that promotes tissue‐specific growth and differentiation of cells in vitro. Tissue Eng. 1998;4(2):157‐174..

    Not in our library10.1089/ten.1998.4.157

  69. 69.

    Keane TJ, DeWard A, Londono R, et al. Tissue‐specific effects of esophageal extracellular matrix. Tissue Eng Part A. 2015;21(17–18):2293‐2300..

    Not in our library10.1089/ten.tea.2015.0322

  70. 70.

    Lin H, Yang G, Tan J, Tuan RS. Influence of decellularized matrix derived from human mesenchymal stem cells on their proliferation, migration and multi‐lineage differentiation potential. Biomaterials. 2012;33(18):4480‐4489..

    Not in our library10.1016/j.biomaterials.2012.03.012

  71. 71.

    Yang G, Rothrauff BB, Lin H, Gottardi R, Alexander PG, Tuan RS. Enhancement of tenogenic differentiation of human adipose stem cells by tendon‐derived extracellular matrix. Biomaterials. 2013;34(37):9295‐9306..

    Not in our library10.1016/j.biomaterials.2013.08.054

  72. 72.
  73. 73.

    Bostrom MPG, Yang X, Kennan M, Sandhu H, Dicarlo E, Lane JM. An unexpected outcome during testing of commercially available demineralized bone graft materials: how safe are the nonallograft components? Spine (Phila Pa 1976). 2001;26(13):1425‐1428..

    Not in our library10.1097/00007632-200107010-00007

  74. 74.

    Acarturk TO, Hollinger JO. Commercially available demineralized bone matrix compositions to regenerate calvarial critical‐sized bone defects. Plast Reconstr Surg. 2006;118(4):862‐873..

    Not in our library10.1097/01.prs.0000232385.81219.87

  75. 75.

    Gruskin E, Doll BA, Futrell FW, Schmitz JP, Hollinger JO. Demineralized bone matrix in bone repair: history and use. Adv Drug Deliv Rev. 2012;64(12):1063‐1077..

    Not in our library10.1016/j.addr.2012.06.008

  76. 76.

    Sawkins MJ, Bowen W, Dhadda P, et al. Hydrogels derived from demineralized and decellularized bone extracellular matrix. Acta Biomater. 2013;9(8):7865‐7873..

    Not in our library10.1016/j.actbio.2013.04.029

  77. 77.

    Paduano F, Marrelli M, White LJ, Shakesheff KM, Tatullo M. Odontogenic differentiation of human dental pulp stem cells on hydrogel scaffolds derived from decellularized bone extracellular matrix and collagen type I. Liu X, ed. PLoS One. 2016;11(2):e0148225.

    Not in our library10.1371/journal.pone.0148225

  78. 78.

    Smith EL, Kanczler JM, Gothard D, et al. Evaluation of skeletal tissue repair, part 1: assessment of novel growth‐factor‐releasing hydrogels in an ex vivo chick femur defect model. Acta Biomater. 2014;10(10):4186‐4196..

    Not in our library10.1016/j.actbio.2014.06.011

  79. 79.

    Smith EL, Kanczler JM, Gothard D, et al. Evaluation of skeletal tissue repair, part 2: enhancement of skeletal tissue repair through dual‐growth‐factor‐releasing hydrogels within an ex vivo chick femur defect model. Acta Biomater. 2014;10(10):4197‐4205..

    Not in our library10.1016/j.actbio.2014.05.025

  80. 80.

    Wu J, Ding Q, Dutta A, et al. An injectable extracellular matrix derived hydrogel for meniscus repair and regeneration. Acta Biomater. 2015;16(1):49‐59..

    Not in our library10.1016/j.actbio.2015.01.027

  81. 81.

    Kwon JS, Yoon SM, Shim SW, et al. Injectable extracellular matrix hydrogel developed using porcine articular cartilage. Int J Pharm. 2013;454(1):183‐191..

    Not in our library10.1016/j.ijpharm.2013.06.023

  82. 82.

    Rothrauff BB, Coluccino L, Gottardi R, et al. Efficacy of thermoresponsive, photocrosslinkable hydrogels derived from decellularized tendon and cartilage extracellular matrix for cartilage tissue engineering. J Tissue Eng Regen Med. 2018;12(1):e159‐e170..

    Not in our library10.1002/term.2465

  83. 83.

    Cheng N‐C, Estes BT, Young T‐H, Guilak F. Genipin‐crosslinked cartilage‐derived matrix as a scaffold for human adipose‐derived stem cell chondrogenesis. Tissue Eng Part A. 2013;19(3–4):484‐496..

    Not in our library10.1089/ten.tea.2012.0384

  84. 84.

    Visser J, Levett PA, te Moller NCR, et al. Crosslinkable hydrogels derived from cartilage, meniscus, and tendon tissue. Tissue Eng Part A. 2015;21(7–8):1195‐1206..

    Not in our library10.1089/ten.tea.2014.0362

  85. 85.

    Kumar A, Nune KC, Misra RDK. Biological functionality of extracellular matrix‐ornamented three‐dimensional printed hydroxyapatite scaffolds. J Biomed Mater Res ‐ Part A. 2016;104(6):1343‐1351..

    Not in our library10.1002/jbm.a.35664

  86. 86.

    Kumar A, Nune KC, Misra RDK. Biological functionality and mechanistic contribution of extracellular matrix‐ornamented three dimensional Ti‐6Al‐4V mesh scaffolds. J Biomed Mater Res ‐ Part A. 2016;104(11):2751‐2763..

    Not in our library10.1002/jbm.a.35809

  87. 87.

    Thibault RA, Scott Baggett L, Mikos AG, Kasper FK. Osteogenic differentiation of mesenchymal stem cells on Pregenerated extracellular matrix scaffolds in the absence of osteogenic cell culture supplements. Tissue Eng Part A. 2010;16(2):431‐440..

    Not in our library10.1089/ten.tea.2009.0583

  88. 88.

    Thibault RA, Mikos AG, Kasper FK. Protein and mineral composition of osteogenic extracellular matrix constructs generated with a flow perfusion bioreactor. Biomacromolecules. 2011;12(12):4204‐4212..

    Not in our library10.1021/bm200975a

  89. 89.

    Liao J, Guo X, Grande‐Allen KJ, Kasper FK, Mikos AG. Bioactive polymer/extracellular matrix scaffolds fabricated with a flow perfusion bioreactor for cartilage tissue engineering. Biomaterials. 2010;31(34):8911‐8920..

    Not in our library10.1016/j.biomaterials.2010.07.110

  90. 90.

    Liao J, Guo X, Nelson D, Kasper FK, Mikos AG. Modulation of osteogenic properties of biodegradable polymer/extracellular matrix scaffolds generated with a flow perfusion bioreactor. Acta Biomater. 2010;6(7):2386‐2393..

    Not in our library10.1016/j.actbio.2010.01.011

  91. 91.

    Kim BS, Choi JS, Kim JD, Choi YC, Cho YW. Recellularization of decellularized human adipose‐tissue‐derived extracellular matrix sheets with other human cell types. Cell Tissue Res. 2012;348(3):559‐567..

    Not in our library10.1007/s00441-012-1391-y

  92. 92.

    Zhang J, Zhang Q, Chen J, et al. Preparation and evaluation of tibia‐ and calvarium‐derived decellularized periosteum scaffolds. ACS Biomater Sci Eng. 2017;3(12):3503‐3514..

    Not in our library10.1021/acsbiomaterials.7b00548

  93. 93.

    Li M, Zhang C, Mao Y, Zhong Y, Zhao J. A cell‐engineered small intestinal submucosa‐based bone mimetic construct for bone regeneration. Tissue Eng Part A. 2018;24(13‐14):1099‐1111..

    Not in our library10.1089/ten.tea.2017.0407

  94. 94.

    Zhang C, Li M, Zhu J, Luo F, Zhao J. Enhanced bone repair induced by human adipose‐derived stem cells on osteogenic extracellular matrix ornamented small intestinal submucosa. Regen Med. 2017;12(5):541‐552..

    Not in our library10.2217/rme-2017-0024

  95. 95.

    Hoshiba T, Yamada T, Lu H, Kawazoe N, Chen G. Maintenance of cartilaginous gene expression on extracellular matrix derived from serially passaged chondrocytes during in vitro chondrocyte expansion. J Biomed Mater Res ‐ Part A. 2012;100 A(3):694‐702..

    Not in our library10.1002/jbm.a.34003

  96. 96.

    Hoshiba T, Lu H, Kawazoe N, Yamada T, Chen G. Effects of extracellular matrix proteins in chondrocyte‐derived matrices on chondrocyte functions. Biotechnol Prog. 2013;29(5):1331‐1336..

    Not in our library10.1002/btpr.1780

  97. 97.

    Tang C, Xu Y, Jin C, et al. Feasibility of autologous bone marrow mesenchymal stem cell‐derived extracellular matrix scaffold for cartilage tissue engineering. Artif Organs. 2013;37(12):E179‐E190..

    Not in our library10.1111/aor.12130

  98. 98.

    Tang C, Jin C, Du X, et al. An autologous bone marrow mesenchymal stem cell–derived extracellular matrix scaffold applied with bone marrow stimulation for cartilage repair. Tissue Eng Part A. 2014;20(17–18):2455‐2462..

    Not in our library10.1089/ten.tea.2013.0464

  99. 99.

    Kang HW, Lee SJ, Ko IK, Kengla C, Yoo JJ, Atala A. A 3D bioprinting system to produce human‐scale tissue constructs with structural integrity. Nat Biotechnol. 2016;34(3):312‐319..

    Not in our library10.1038/nbt.3413

  100. 100.

    Bittner SM, Guo JL, Melchiorri A, Mikos AG. Three‐dimensional printing of multilayered tissue engineering scaffolds. Mater Today. 2018 In Press..

    Not in our library10.1016/j.mattod.2018.02.006

  101. 101.

    Pati F, Jang J, Ha DH, et al. Printing three‐dimensional tissue analogues with decellularized extracellular matrix bioink. Nat Commun. 2014;5:3935.

    Not in our library10.1038/ncomms4935

  102. 102.

    Skardal A, Devarasetty M, Kang HW, et al. A hydrogel bioink toolkit for mimicking native tissue biochemical and mechanical properties in bioprinted tissue constructs. Acta Biomater. 2015;25:24‐34..

    Not in our library10.1016/j.actbio.2015.07.030

  103. 103.

    Jang J, Kim TG, Kim BS, Kim S‐W, Kwon S‐M, Cho D‐W. Tailoring mechanical properties of decellularized extracellular matrix bioink by vitamin B2‐induced photo‐crosslinking. Acta Biomater. 2016;33:88‐95..

    Not in our library10.1016/j.actbio.2016.01.013

  104. 104.

    Duan Y, Liu Z, O'Neill J, Wan LQ, Freytes DO, Vunjak‐Novakovic G. Hybrid gel composed of native heart matrix and collagen induces cardiac differentiation of human embryonic stem cells without supplemental growth factors. J Cardiovasc Transl Res. 2011;4(5):605‐615..

    Not in our library10.1007/s12265-011-9304-0

  105. 105.

    Singelyn JM, DeQuach JA, Seif‐Naraghi SB, Littlefield RB, Schup‐Magoffin PJ, Christman KL. Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering. Biomaterials. 2009;30(29):5409‐5416..

    Not in our library10.1016/j.biomaterials.2009.06.045

  106. 106.

    Shevach M, Zax R, Abrahamov A, Fleischer S, Shapira A, Dvir T. Omentum ECM‐based hydrogel as a platform for cardiac cell delivery. Biomed Mater. 2015;10(3):034106.

    Not in our library10.1088/1748-6041/10/3/034106

  107. 107.

    Hollister SJ. Porous scaffold design for tissue engineering. Nat Mater. 2005;4(7):518‐524..

    Not in our library10.1038/nmat1421

  108. 108.

    Loebel C, Rodell CB, Chen MH, Burdick JA. Shear‐thinning and self‐healing hydrogels as injectable therapeutics and for 3D‐printing. Nat Protoc. 2017;12(8):1521‐1541..

    Not in our library10.1038/nprot.2017.053

  109. 109.

    Chen CW, Wang LL, Zaman S, et al. Sustained release of endothelial progenitor cell‐derived extracellular vesicles from shear‐thinning hydrogels improves angiogenesis and promotes function after myocardial infarction. Cardiovasc Res. March 2018;114:1029‐1040..

    Not in our library10.1093/cvr/cvy067

  110. 110.

    Wang LL, Highley CB, Yeh YC, Galarraga JH, Uman S, Burdick JA. Three‐dimensional extrusion bioprinting of single‐ and double‐network hydrogels containing dynamic covalent crosslinks. J Biomed Mater Res ‐ Part A. 2018;106(4):865‐875..

    Not in our library10.1002/jbm.a.36323

  111. 111.

    Townsend JM, Dennis SC, Whitlow J, et al. Colloidal gels with extracellular matrix particles and growth factors for bone regeneration in critical size rat calvarial defects. AAPS J. 2017;19(3):703‐711..

    Not in our library10.1208/s12248-017-0045-0

  112. 112.

    Chang CH, Chen CC, Liao CH, Lin FH, Hsu YM, Fang HW. Human acellular cartilage matrix powders as a biological scaffold for cartilage tissue engineering with synovium‐derived mesenchymal stem cells. J Biomed Mater Res ‐ Part A. 2014;102(7):2248‐2257..

    Not in our library10.1002/jbm.a.34897

  113. 113.

    Beachley V, Ma G, Papadimitriou C, Gibson M, Corvelli M, Elisseeff J. Extracellular matrix particle–glycosaminoglycan composite hydrogels for regenerative medicine applications. J Biomed Mater Res ‐ Part A. 2018;106(1):147‐159..

    Not in our library10.1002/jbm.a.36218

  114. 114.

    Masaeli E, Karamali F, Loghmani S, Eslaminejad MB, Nasr‐Esfahani MH. Bio‐engineered electrospun nanofibrous membranes using cartilage extracellular matrix particles. J Mater Chem B. 2017;5(4):765‐776..

    Not in our library10.1039/c6tb02015a

  115. 115.

    Butscher A, Bohner M, Hofmann S, Gauckler L, Müller R. Structural and material approaches to bone tissue engineering in powder‐based three‐dimensional printing. Acta Biomater. 2011;7(3):907‐920..

    Not in our library10.1016/j.actbio.2010.09.039

  116. 116.

    Bose S, Vahabzadeh S, Bandyopadhyay A. Bone tissue engineering using 3D printing. Mater Today. 2013;16(12):496‐504..

    Not in our library10.1016/j.mattod.2013.11.017

  117. 117.
  118. 118.

    Shor L, Güçeri S, Wen X, Gandhi M, Sun W. Fabrication of three‐dimensional polycaprolactone/hydroxyapatite tissue scaffolds and osteoblast‐scaffold interactions in vitro. Biomaterials. 2007;28(35):5291‐5297..

    Not in our library10.1016/j.biomaterials.2007.08.018

  119. 119.

    Koh YH, Jun IK, Kim HE. Fabrication of poly(ε‐caprolactone)/hydroxyapatite scaffold using rapid direct deposition. Mater Lett. 2006;60(9–10):1184‐1187..

    Not in our library10.1016/j.matlet.2005.10.103

  120. 120.

    Park SA, Lee SH, Kim WD. Fabrication of porous polycaprolactone/hydroxyapatite (PCL/HA) blend scaffolds using a 3D plotting system for bone tissue engineering. Bioprocess Biosyst Eng. 2011;34(4):505‐513..

    Not in our library10.1007/s00449-010-0499-2

  121. 121.

    Hung BP, Naved BA, Nyberg EL, et al. Three‐dimensional printing of bone extracellular matrix for craniofacial regeneration. ACS Biomater Sci Eng. 2016;2(10):1806‐1816..

    Not in our library10.1021/acsbiomaterials.6b00101

  122. 122.

    Nyberg E, Rindone A, Dorafshar A, Grayson WL. Comparison of 3D‐printed poly‐ε‐caprolactone scaffolds functionalized with tricalcium phosphate, hydroxyapatite, bio‐Oss, or decellularized bone matrix. Tissue Eng Part A. 2017;23(11–12):503‐514..

    Not in our library10.1089/ten.tea.2016.0418

  123. 123.

    Yin H, Wang Y, Sun Z, et al. Induction of mesenchymal stem cell chondrogenic differentiation and functional cartilage microtissue formation for in vivo cartilage regeneration by cartilage extracellular matrix‐derived particles. Acta Biomater. 2016;33:96‐109..

    Not in our library10.1016/j.actbio.2016.01.024

  124. 124.

    Teng Y, Li X, Chen Y, et al. Extracellular matrix powder from cultured cartilage‐like tissue as cell carrier for cartilage repair. J Mater Chem B. 2017;5(18):3283‐3292..

    Not in our library10.1039/c7tb00640c

Cited by papers we hold 6

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.